These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35607951)

  • 21. Association between renin-angiotensin antagonism and COVID-19-related mortality in patients with essential hypertension: A single center, retrospective cohort study.
    Kamalumpundi V; Kawasaki S; Cheng L; Meyers EE; Shams E; Ofori O; Eddin A; Correia MLG
    J Clin Hypertens (Greenwich); 2024 Sep; 26(9):1039-1044. PubMed ID: 39003579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
    Melissa Hallow K; Dave I
    Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
    Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM
    J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 and renin-angiotensin system modulators: what do we know so far?
    de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
    Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
    Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
    Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
    Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
    Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
    Barone M; Viggiani MT; Losurdo G; Principi M; Leo AD
    World J Gastroenterol; 2019 May; 25(20):2524-2538. PubMed ID: 31171895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
    Sriram K; Loomba R; Insel PA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29274-29282. PubMed ID: 33203679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.
    Gormez S; Ekicibasi E; Degirmencioglu A; Paudel A; Erdim R; Gumusel HK; Eroglu E; Tanboga IH; Dagdelen S; Sariguzel N; Kirisoglu CE; Pamukcu B
    J Hum Hypertens; 2021 Jul; 35(7):588-597. PubMed ID: 32839534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
    Savoia C; Volpe M; Kreutz R
    Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
    Bauer A; Schreinlechner M; Sappler N; Dolejsi T; Tilg H; Aulinger BA; Weiss G; Bellmann-Weiler R; Adolf C; Wolf D; Pirklbauer M; Graziadei I; Gänzer H; von Bary C; May AE; Wöll E; von Scheidt W; Rassaf T; Duerschmied D; Brenner C; Kääb S; Metzler B; Joannidis M; Kain HU; Kaiser N; Schwinger R; Witzenbichler B; Alber H; Straube F; Hartmann N; Achenbach S; von Bergwelt-Baildon M; von Stülpnagel L; Schoenherr S; Forer L; Embacher-Aichhorn S; Mansmann U; Rizas KD; Massberg S;
    Lancet Respir Med; 2021 Aug; 9(8):863-872. PubMed ID: 34126053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.